Clinical Trials
36 trialsA Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib Therapy
GlaxoSmithKline
(Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors
Cogent Biosciences, Inc.
A Study to Investigate Velzatinib Compared With Imatinib in Adult Participants With Previously Untreated Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (StrateGIST Frontline)
GlaxoSmithKline
INTRIGUE
Deciphera Pharmaceuticals, LLC
INSIGHT
Deciphera Pharmaceuticals, LLC
Efficacy and Safety of Famitinib Versus Sunitinib in the Treatment of Advanced Gastrointestinal Stromal Tumour Patients After Failure of Imatinib
Jiangsu HengRui Medicine Co., Ltd.
ImadGist
Centre Leon Berard
PIRKER
Fujian Medical University Union Hospital
Masitinib in First Line Treatment of Gastro-Intestinal Stromal Tumor (GIST)
AB Science
INVICTUS
Deciphera Pharmaceuticals, LLC
(VOYAGER) Study of Avapritinib vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic GIST
Blueprint Medicines Corporation
GRID
Bayer
Masitinib in Patients With Gastrointestinal Stromal Tumour After Progression With Imatinib
AB Science
L-carnitine vs Placebo for the Treatment of Muscle Cramps After Imatinib in Gastrointestinal Stromal Tumors
Asan Medical Center
Rechallenge of Imatinib in GIST Having no Effective Treatment: RIGHT
Asan Medical Center
Imatinib Mesylate or Observation Only in Treating Patients Who Have Undergone Surgery for Localized Gastrointestinal Stromal Tumor
European Organisation for Research and Treatment of Cancer - EORTC
COMTT
Impaqtt Foundation
S0502
National Cancer Institute (NCI)
Efficacy of Nilotinib in Adult Patients With Gastrointestinal Stromal Tumors Resistant to Imatinib and Sunitinib.
Novartis
EUS-FNB vs. Single-incision Needle-knife (SINK) Biopsy for Gastrointestinal SELs
Unity Health Toronto
ENESTg1
Novartis
Detection of CF-DNA in Patients With Gastrointestinal Stromal Tumors (GIST)
Technical University of Munich
GIGIST
Assistance Publique Hopitaux De Marseille
Open-label Trial of GlivecWith Unresectable or Metastatic Malignant Gastrointestinal Stromal Tumors
Central European Cooperative Oncology Group
Comparison of Two Different Doses of STI571 in Treating Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumor
National Cancer Institute (NCI)
Imatinib Mesylate in Treating Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumor
European Organisation for Research and Treatment of Cancer - EORTC
MACS0375
Novartis
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain
INSYS Therapeutics Inc
Study of Dose Escalation Versus no Dose Escalation of Imatinib in Metastatic Gastrointestinal Stromal Tumors (GIST) Patients
Sarcoma Alliance for Research through Collaboration
Imatinib Mesylate in Treating Patients With Primary Gastrointestinal Stromal Tumor That Has Been Completely Removed By Surgery
National Cancer Institute (NCI)
Study Evaluating IPI-504 in Patients With Gastrointestinal Stromal Tumors (GIST) Following Failure of at Least Imatinib and Sunitinib
Infinity Pharmaceuticals, Inc.
Imatinib Mesylate With or Without Surgery in Treating Patients With Metastatic Gastrointestinal Stromal Tumor That is Responding to Imatinib Mesylate
European Organisation for Research and Treatment of Cancer - EORTC
ENEST
Novartis
Study Comparing 12 Months Versus 36 Months of Imatinib in the Treatment of Gastrointestinal Stromal Tumor (GIST)
Scandinavian Sarcoma Group
Safety And Effectiveness Of Daily Dosing With Sunitinib Or Imatinib In Patients With Gastrointestinal Stromal Tumors
Pfizer
A Study To Assess The Safety And Efficacy Of SU11248 In Patients With Gastrointestinal Stromal Tumor(GIST)
Pfizer